Notwithstanding the current knowledge regarding the biological role of PARP and its demonstrated clinical benefit in cancers with germline BRCA mutations, future studies are needed to improve the therapeutic potential of PARP inhibitors. The gene discussed is PARP1; the disease is cancer.